342611-08-9
342611-08-9
Chemical Structure
Benzocaine-d4
- CAS No.: 342611-08-9
- Formula:C9H7D4NO2
- Molecular Weight:169.21
IUPAC Name: ethyl 4-aminobenzoate-2,3,5,6-d4
InChIKey: BLFLLBZGZJTVJG-LNFUJOGGSA-N
SMILES: CCOC(C1=C([2H])C([2H])=C(C([2H])=C1[2H])N)=O
Biological Activity: Benzocaine-d4 is the deuterium labeled Benzocaine (HY-Y0258). Benzocaine is an orally active local anesthetic. Benzocaine non-competitively inhibits the binding of Ca-ATPase to Ca2+, with an IC50 of 47.1 mM. Benzocaine exerts anesthetic effects by blocking voltage-gated sodium channels. Benzocaine induces methemoglobinemia in various experimental animals[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Benzocaine-d4 | 99.34% | Benzocaine-d4 is the deuterium labeled Benzocaine (HY-Y0258). Benzocaine is an orally active local anesthetic. Benzocaine non-competitively inhibits the binding of Ca-ATPase to Ca2+, with an IC50 of 47.1 mM. Benzocaine exerts anesthetic effects by blocking voltage-gated sodium channels. Benzocaine induces methemoglobinemia in various experimental animals. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Benzocaine (Standard) | 99.99% | Benzocaine (Standard) is the analytical standard of Benzocaine (HY-Y0258). This product is intended for research and analytical applications. Benzocaine is an orally active local anesthetic. Benzocaine non-competitively inhibits the binding of Ca-ATPase to Ca2+, with an IC50 of 47.1 mM. Benzocaine exerts anesthetic effects by blocking voltage-gated sodium channels. Benzocaine induces methemoglobinemia in various experimental animals. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Benzocaine-(ethyl-d5) | 99.0% | Benzocaine-(ethyl-d5) is the deuterium labeled Benzocaine (HY-Y0258). Benzocaine is an orally active local anesthetic. Benzocaine non-competitively inhibits the binding of Ca-ATPase to Ca2+, with an IC50 of 47.1 mM. Benzocaine exerts anesthetic effects by blocking voltage-gated sodium channels. Benzocaine induces methemoglobinemia in various experimental animals. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Benzocaine | 99.82% | Benzocaine is an orally active local anesthetic. Benzocaine non-competitively inhibits the binding of Ca-ATPase to Ca2+, with an IC50 of 47.1 mM. Benzocaine exerts anesthetic effects by blocking voltage-gated sodium channels. Benzocaine induces methemoglobinemia in various experimental animals. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Wang GK et al. A common local anesthetic receptor for benzocaine and etidocaine in voltage-gated mu1 Na+ channels. Pflugers Arch. 1998 Jan;435(2):293-302. [Content Brief]
- [3]. Davis JA, et al. Benzocaine-induced methemoglobinemia attributed to topical application of the anesthetic in several laboratory animal species. Am J Vet Res. 1993 Aug;54(8):1322-6. [Content Brief]
